Articles tagged with Immunological Techniques
Scientists at UVA have developed a new method to target glioblastoma, the most common and deadly brain cancer, by delivering microRNAs through the brain's natural barrier. The approach shows promise in slowing tumor growth and extending survival in animal models.
The new journal features cutting-edge research across basic, clinical, and translational immunology. It is designed to connect researchers across the full breadth of immunology, deepening understanding of the immune system in health and disease.
The article systematically summarizes forty years of discoveries in the TLR field, revealing multilayered regulatory mechanisms governing TLR signaling. Aberrant TLR signaling is closely linked to multiple human diseases, including infectious diseases, autoimmune conditions, and cancer.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
A retrospective study of 40 immunocompromised ICU patients found associations between low CD4+T-cell counts and specific lung pathogens. Patients with severe CD4 depletion had higher proportions of fungal infections, while moderate immunosuppression was linked to Streptococcus pneumoniae.
Researchers propose a new conceptual framework for neutrophils, highlighting their dynamic and adaptable nature. The study reveals neutrophils' functional diversification and immunological memory capabilities, opening avenues for innovative therapeutic strategies.
Recent advances in immunotherapy have transformed multiple myeloma treatment, offering durable survival benefits. Emerging targets such as regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages are being explored to enhance treatment efficacy.
Researchers at MD Anderson have made significant discoveries in the treatment of rare bile duct cancers, with zanidatamab showing promising results. Additionally, a study identified RASH3D19 as a target to overcome treatment resistance in KRAS-mutant cancers.
Researchers discovered that cardiac fibroblasts use a signaling pathway to promote harmful changes in the heart, weakening its ability to pump blood efficiently. Blocking this pathway in mice models improved heart function, suggesting that fibroblasts could be a potential target for new therapeutic strategies.
Researchers from Ateneo de Manila University have identified key proteins produced by Helicobacter pylori that can trigger a strong immune response. By analyzing these proteins using immunoinformatics, the team has pinpointed potential vaccine targets to prevent stomach ulcers and cancer.
Researchers have identified a secreted form of a protein called Clever-1 that systemically suppresses T cells essential for fighting cancer. The investigational anti-Clever-1 antibody, bexmarilimab, directly inhibits the release of sClever-1, potentially predicting treatment resistance and paving the way for new combination treatments.
Researchers at UMass Amherst found that certain T-cells have an inherent ability to remember past viral foes, which could lead to next-generation cancer vaccines. This 'immunological memory' is crucial for the body's immune response and can be harnessed for targeted therapies.
Researchers at NUS have developed a bioengineering approach to keep human lymph node tissue alive and functioning outside the body for several days. The method involves embedding thin slices of lymph node tissue in a soft gel that mimics the body's natural environment, allowing for detailed studies of immune cell behavior.
A proof-of-concept study shows that chimeric antigen receptors (CARs) can distinguish between tau tangles and various forms of toxic amyloid plaques, two key contributors to Alzheimer's disease pathology. The technology has the potential to deliver therapeutic drugs directly to affected areas of the brain with reduced side effects.
Scientists have engineered a herpes virus to activate pathways in T cells, enhancing their ability to fight cancer. The approach uses proteins from the herpes virus to recruit enzymes that sustain T cell function in tumors.
A team of researchers has identified a novel oncometabolite that accumulates in tumors and impairs immune cells' ability to fight cancer. The study highlights how the metabolic environment of tumors influences T cell function, opening new possibilities for improving cancer immunotherapy by targeting tumor metabolism.
Pamela J. Bjorkman, K. Christopher Garcia, and Ian A. Wilson receive inaugural prize for their groundbreaking research in structural immunology, which has paved the way for novel disease treatments and revealed new insights into the immune system.
A new study has found that children raised in rural areas with plenty of outdoor time and animal exposure develop better-regulated immune systems than urban counterparts. Early life immune development is highly dependent on living environment and lifestyle factors, and researchers say this can have long-term consequences for disease risk.
Researchers at Aarhus University have discovered a new method to activate the complement system using bispecific single-domain antibodies, termed BiCEs. These molecules can specifically target cancer cells and activate the complement system, leading to the killing of targeted cancer cells.
Researchers discuss the potential of glucocorticoid-induced TNFR-related protein (GITR) as a target for cancer immunotherapy. Preclinical studies have shown potent anti-tumor efficacy, but clinical trials have yielded inconsistent results due to complexities in immune responses and antibody structure.
Researchers developed a new test method to detect tuberculosis (TB) progression from latent infection in elephants using IgG antibodies against Antigen 85B. High levels of IgG against ESAT6/CFP10 remained constant, while IgG against Ag85B increased before disease onset and declined with treatment.
Researchers at Karolinska Institutet have developed a method to identify the immune cells involved in autoimmune diseases and identified four new target molecules for personalized treatment of multiple sclerosis. This approach could lead to more precise treatments with fewer side effects, potentially benefiting other autoimmune diseases.
Katalin Karikó, a Hungarian-born biochemist, received the 2022 Vilcek Prize for Excellence in Biotechnology for her decades-long research leading to the development of safe and effective mRNA vaccines. Her work has had a profound impact on culture and society, particularly in the fight against COVID-19.
Dixit's work on programmed cell death and inflammation has led to therapies for autoimmune disorders and rheumatoid arthritis. The Vilcek Foundation recognizes his contributions as an immigrant scientist in the US.